San Diego – September 10, 2026 -- Robbins LLP has filed a securities class action against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025 and February 24, 2026, alleging the company misrepresented the safety and commercial viability of its iLet Bionic Pancreas insulin pump.
FDA warning letter contradicts prior company statements on device complaints
The complaint alleges that in October 2025, Beta Bionics disclosed an FDA Form 483 but told investors the issue was limited to complaint-reporting classification, not device safety, and that only minor customer complaints needed backfiling. Plaintiffs allege the FDA had in fact identified device malfunctions causing dangerously high insulin dosing and hypoglycemic events, with complaints numbering in the thousands and hundreds involving life-threatening incidents requiring medical intervention.
Stock lost 60% of value following February 24 FDA disclosure
Beta Bionics shares traded at $31.99 on January 9, 2026, before falling to $12.89 by February 25, 2026, after the FDA publicly released its warning letter detailing unresolved violations. The disclosure contradicted months of management assurances that all backfiled complaints involved benign issues requiring no ongoing corrective action.
Lead plaintiff deadline set for November 3, 2026
Investors who acquired Beta Bionics shares during the class period may seek lead plaintiff status ahead of the November 3, 2026 deadline. A lead plaintiff is court-appointed to represent the class but is not required to secure a recovery; other investors may remain absent class members. Robbins LLP is pursuing the case on a contingency-fee basis, meaning class members incur no direct cost to participate.